Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection.
Mohanad M Al-ObaidiAhmet B GungorSaman NematollahiTirdad T ZangenehEdward J BedrickKatherine M JohnsonNicole E Low-AdegbijaRuhaniyah AlamPooja RanganC William HeiseVenkatesh K AriyamuthuAneesha ShettyAbd Assalam QannusSangeetha MurugapandianMehmet M S AyvaciPrince Mohan AnandBekir TanrioverPublished in: Open forum infectious diseases (2022)
Cas-Imd mAb treatment was associated with a lower hospitalization rate, ICU admission, and mortality within 30 days among patients infected with the SARS-CoV-2 Delta variant.